ASH18: Bluebird's follow-on CAR-T finds initial success, but durability will be key test

Bluebird bio's lead CAR-T candidate captured the industry's attention over the last two years with promising clinical readouts. But on Sunday, it was the company's second-generation cell therapy that stood in the spotlight, as data on a small group of very sick multiple myeloma patients showed the treatment to be effective.